In 2008 3Di carried out an appraisal of AstraZeneca's bulk drug manufacturing facility in Macclesfield to assess whether any of the surplus assets could be salvaged. Following the successful 2 day appraisal and valuation 3Di were asked to prepare a marketing and sales programme for the surplus assets.

In 2009 AstraZeneca instructed 3Di to begin marketing the assets prior to ending of the production at the facility. The assets include a large quantity of hastelloy and stainless steel filter dryers, hastelloy and glass lined reactors, hastelloy charging booths, Alpine milling plants, Hosoakawa jet mill plants and much more.

3Di are currently selling the assets via Private Treaty Sale, please visit our asset disposals section for a complete list of the assets for sale.